Related Experiment Video
Updated: May 31, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Repeated phlebotomies improve and stabilise renal function in cyanotic nephropathy
Kennedy O Omonuwa1, Arunabh Talwar, Sophy Dedopoulos
1North Shore University Hospital, Department of Pulmonary, Critical Care and Sleep Medicine, Suite 107, 410 Lakeville Road, New Hyde Park, NY 11042, USA.
Insights
Phlebotomy offers a potential treatment for cyanotic nephropathy in patients with cyanotic congenital heart disease (CCHD) who cannot tolerate ACE inhibitors, improving renal function.
Area of Science:
- Nephrology
- Cardiology
- Vascular Biology
Background:
- Cyanotic congenital heart disease (CCHD) can lead to cyanotic nephropathy, characterized by glomerular proteinuria.
- The exact cause of CCHD-associated glomerulopathy is unknown, but hyperviscosity potentially reduces blood flow in peritubular capillaries, increasing glomerular pressure and causing proteinuria.
- Angiotensin-converting enzyme (ACE) inhibitors are a common treatment but may not be tolerated by all patients.
Purpose of the Study:
- To present a case study of an adult patient with CCHD and cyanotic nephropathy.
- To explore an alternative treatment for patients intolerant to ACE inhibitors.
Main Methods:
- A case report of an adult female patient with CCHD.
- Treatment with repeated phlebotomies after intolerance to ACE inhibitors.
Main Results:
- The patient showed improvement and stabilization of renal function after phlebotomy treatment.
- Phlebotomy was a viable alternative for managing cyanotic nephropathy in this patient.
Conclusions:
- Phlebotomy can be an effective treatment for cyanotic nephropathy in CCHD patients who cannot tolerate ACE inhibitors.
- This case highlights the potential of phlebotomy in managing renal complications of CCHD.
Abstract:
Patients over 10 years of age with cyanotic congenital heart disease (CCHD) risk developing significant glomerular proteinuria, a condition called cyanotic nephropathy. Even though the pathogenesis of glomerulopathy associated with CCHD is still unclear, a potential mechanism is hyperviscosity-induced decrease in peritubular capillary blood flow leading to an increase in glomerular capillary pressure, in turn resulting in proteinuria. Although angiotensin-converting enzyme (ACE) inhibitors have been traditionally used in the treatment of these patients with cyanotic nephropathy, they may, however, not be well tolerated. Here we present a case of an adult patient with CCHD who could not tolerate an ACE inhibitor but showed improvement and stabilisation of her renal function following treatment with repeated phlebotomies.
Related Concept Videos
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
